Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2
Noralane M. Lindor(Mayo Clinic in Arizona), Rosario Alonso(Spanish National Cancer Research Centre), Guillermo Pita(Spanish National Cancer Research Centre), K-r Ong(Helsinki University Hospital), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust), Fergus J. Couch(Mayo Clinic), Gillian Douglas(Institute of Genetics and Cancer), Cees E. Van Roozendaal(University of Cambridge), Julian Adlard(Chapel Allerton Hospital), Marjolijn J. L. Ligtenberg(Radboud University Nijmegen), Quinten Waisfisz(University Medical Center Utrecht), Louise Izatt(Guy's and St Thomas' NHS Foundation Trust), Ana Osório(Spanish National Cancer Research Centre), Roger L. Milne(The University of Melbourne), Margreet G.E.M. Ausems(McGill University Health Centre), Cora M. Aalfs(University of Amsterdam), Maaike P.G. Vreeswijk(Leiden University Medical Center), Douglas F. Easton(University of Cambridge), Irene Konstantopoulou(National Centre of Scientific Research "Demokritos"), Mark Cook(St Vincent's Hospital Melbourne), Lyndon Walker(Churchill Hospital), Heli Nevanlinna(University of Helsinki), Adriana Lasa(Hospital de Sant Pau), C. J. van Asperen(Leiden University), Susan M. Domchek(University City Science Center), Agnes Jager(Erasmus MC Cancer Institute), Katherine L. Nathanson(Translational Therapeutics (United States)), Sarah Downing(Mayo Clinic), Àlex Teulé(Institut d'Investigació Biomédica de Bellvitge), D. Gareth Evans(Manchester Academic Health Science Centre), Clare T Oliver(University of Cambridge), D Frost(Guy's and St Thomas' NHS Foundation Trust), Paolo Peterlongo(IFOM), Frans B.L. Hogervorst(The Netherlands Cancer Institute), Kristiina Aittomäki(University of Helsinki), Zachary Fredericksen(Karolinska University Hospital), R Davidson(Southern General Hospital), Timothy R. Rebbeck(University of Pennsylvania), C Brewer(Royal Devon and Exeter Hospital), Senno Verhoef(The Netherlands Cancer Institute), S. Peock(University of Cambridge), M. F. van Dooren, Fiona Lalloo(Manchester Academic Health Science Centre), B Curzon(University of Cambridge), Diana Eccles(Princess Anne Hospital)
Cited by 9
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k